Description

Arrowhead Pharmaceuticals’ $45,000 REDEMPLO Launch: Can RNAi Scale Beyond Rare Disease?

Arrowhead Pharmaceuticals is progressing through a pivotal transitional phase marked by the recent commercial launch of REDEMPLO, an FDA-approved RNAi-based therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels. The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base predominantly naive to similar APOC3 inhibitors. The company’s pricing strategy—set at a wholesale acquisition cost (WAC) of $45,000 annually, a premium over competitors—is supported by clinical data signaling superior triglyceride reduction, safety, and dosing convenience. Reimbursement discussions with payers show promising momentum, with flexible diagnostic criteria improving patient access. International regulatory approvals have been secured in several major markets, including Australia, China, Canada, and a positive opinion from the European Medicines Agency, with launches anticipated later in 2026.